Occudo Quantitative Strategies LP Adverum Biotechnologies, Inc. Transaction History

Occudo Quantitative Strategies LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.68 - $1.59 $22,527 - $52,673	-33,128 Reduced 63.03%	19,432 $30,000
Q1 2023 May 15, 2023	SELL	$0.62 - $0.85 $15,982 - $21,912	-25,779 Reduced 32.91%	52,560 $37,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $939 - $17,922	-1,740 Reduced 2.17%	78,339 $45,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $55,000 - $87,196	-44,716 Reduced 35.83%	80,079 $105,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $36,776 - $50,726	21,136 Added 20.39%	124,795 $220,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $38,594 - $66,798	18,555 Added 21.8%	103,659 $225,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $222,442 - $699,103	66,203 Added 350.26%	85,104 $298,000
Q1 2021 May 14, 2021	SELL	$9.26 - $14.36 $402,282 - $623,841	-43,443 Reduced 69.68%	18,901 $186,000
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $613,464 - $889,025	62,344 New	62,344 $676,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.